We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
6
2 active
Approvals
124
Total approvals
Agencies
4
Regulatory bodies
Founded
N/A
Completed
66.7%
Not yet recruiting
2
33.3%
CANADA
Health Canada
70
PHILIPPINES
Philippines FDA
25
SFDA
Saudi Food and Drug Authority
NPRA
National Pharmaceutical Regulatory Agency
23
- Jubilant Generics received tentative USFDA approval for Pantoprazole Sodium Delayed Release Oral Suspension, 40 mg per packet, following a successful pre-approval inspection at its Roorkee facility. - The tentative approval will convert to final approval upon patent expiry of the reference listed drug, expected in December 2026. - The approval strengthens Jubilant Pharmova's U.S. generics portfolio in the gastrointestinal therapy segment and positions the company for a prompt commercial launch. - The regulatory milestone was disclosed to Indian stock exchanges under SEBI regulations on June 25, 2026.
